Ovarian reserve in patients with FMR1 gene premutation and the role of fertility preservation.

FXDOR FXPOI fertility preservation fragile X syndrome primary ovarian insufficiency

Journal

Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744

Informations de publication

Date de publication:
01 May 2024
Historique:
received: 15 12 2023
revised: 12 04 2024
accepted: 22 04 2024
medline: 4 5 2024
pubmed: 4 5 2024
entrez: 3 5 2024
Statut: aheadofprint

Résumé

Women with premutation (PM) of the FMR1 gene may suffer from reduced ovarian reserve or even premature ovarian insufficiency (POI). We studied hormonal and ultrasound ovarian reserve, fertility and fertility preservation outcomes in these patients. Retrospective cohort study of 63 female FMR1 premutation carriers. Sixty-three female patients bearing an FMR1 premutation were included. Median age was 30 years [26.5-35]. Median number of CGG triplets was 83 [77.2-92]. Before diagnosis of PM, 19 women (30%) had had in all 35 pregnancies, resulting in 20 births, including 7 affected children. After diagnosis of PM, 17 women (26.1%) had in all 23 pregnancies, at a median age of 34.5 years [32.2-36.0]: 2 after preimplantation genetic diagnosis, 3 after oocyte donation, 18 spontaneously, and 5 ending in medical termination for Fragile X syndrome. Thirty-three patients (52.4%) had POI diagnosis (median age, 30 years [27-34]) with median FSH level 84 IU/L [50.5-110] and median AMH level 0.08 ng/ml [0.01-0.19]. After POI diagnosis, 8 women had in all 9 pregnancies: 3 following oocyte donation, and 6 spontaneous in 5 women (15.1%). Eight of the 9 pregnancies resulted in a live birth (including 2 affected children) and 1 in medical termination for trisomy 13. The median age of the 30 patients without POI was 31 years [25.2-35.0]. Thirteen women (20.6%) underwent fertility preservation, at a median age of 29 years [24-33]: FSH 7.7 IU/L [6.8-9.9], AMH 1.1 ng/mL [0.95-2.1], antral follicle count 9.5 [7.7-14.7]. A median 15 oocytes [10-26] were cryopreserved in a median 2 cycles [1-3]. At the time of writing, no oocytes had yet been thawed for in vitro fertilization. This study shows the importance of early fertility preservation after diagnosis of FMR1 premutation in women, due to early deterioration of ovarian reserve. Genetic counseling is essential in these patients, as spontaneous pregnancies are not uncommon, even in cases of impaired ovarian reserve, and can lead to birth of affected children.

Identifiants

pubmed: 38702011
pii: S0003-4266(24)00052-0
doi: 10.1016/j.ando.2024.04.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Auteurs

Tiphaine Le Poulennec (TL)

AP-HP, IE3M, Hôpital Pitié-Salpêtrière, Departement of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des pathologies gynécologiques rares, Paris, France, Sorbonne Université Médecine, Paris, France, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital, 75 013 PARIS, FRANCE. Electronic address: tiphaine.lepoulennec@aphp.fr.

Sophie Dubreuil (S)

AP-HP, IE3M, Hôpital Pitié-Salpêtrière, Departement of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des pathologies gynécologiques rares, Paris, France, Sorbonne Université Médecine, Paris, France, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital, 75 013 PARIS, FRANCE.

Michael Grynberg (M)

AP-HP, Hôpital Béclère, Departement of Reproductive Medicine Clamart, France, Hôpital Béclère, 157 rue de la Porte de Trivaux, 92140 Clamart, FRANCE.

Nathalie Chabbert-Buffet (N)

AP-HP Hôpital Tenon, Departement of Obstetrics Gynecology and Reproductive Medicine, Sorbonne Université Médecine, Paris, France, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, FRANCE.

Nathalie Sermondade (N)

AP-HP Hôpital Tenon, Departement of Reproductive Biology, Sorbonne Université Médecine, Paris France, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, FRANCE.

Salma Fourati (S)

AP-HP, Hôpital Pitié-Salpêtrière-Charles Foix, Departement of Endocrine Biochemistry and oncology, Paris, France, Sorbonne Université Médecine, Paris, France, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital, 75 013 PARIS, France.

Jean-Pierre Siffroi (JP)

AP-HP, Hôpital Armand Trousseau, Genetics Departement,, INSERM UMR_S_933 Paris, France, Hôpital Armand Trousseau, 26 avenue du Dr Arnold Netter, 75012 Paris, FRANCE.

Delphine Héron (D)

AP-HP, Hôpital Pitié-Salpêtrière, Genetics Department, Paris, France, Sorbonne Université Médecine, Paris, France, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital, 75013 PARIS, FRANCE.

Anne Bachelot (A)

AP-HP, IE3M, Hôpital Pitié-Salpêtrière, Departement of Endocrinology and Reproductive Medicine and Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Référence des pathologies gynécologiques rares, Paris, France, Sorbonne Université Médecine, Paris, France, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital, 75 013 PARIS, FRANCE.

Classifications MeSH